Treatment with MA demonstrated an accumulation of LC3-II autophagosome marker and increased p62 levels in pancreatic and breast cancer cells, indicating a disruption in autophagosome turnover (Kallifatidis et al., 2013; Wang et al., 2023). The gene discussed is MAP1LC3A; the disease is breast cancer.